Hyperlipidemia
Guidelines
-
Stone NJ, Robinson J, Lichtenstein AH, et al.
-
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW;
-
European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D;
-
The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011 Eur Heart J. 2014 Apr;35(15):960-8 .
Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, Catapano AL, Reiner Ž, Lüscher TF.
Original research
-
Lambert G, Petrides F, Chatelais M, Blom DJ, Choque B, Tabet F, Wong G, Rye KA, Hooper AJ, Burnett JR, Barter PJ, Marais AD.
-
Michael J. Koren, MD; Pernille Lundqvist, MD; Michael Bolognese, MD; Joel M. Neutel, MD; Maria Laura Monsalvo, MD; Jingyuan Yang, PhD; Jae B. Kim, MD; Rob Scott, MD; Scott M. Wasserman, MD;
-
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R; LAPLACE-2 Investigators.
-
Stroes E, Colquhoun D, Sullivan D, et al.
-
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA;
-
Desai NR, Giugliano RP, Zhou J, Kohli P, Somaratne R, Hoffman E, Liu T, Scott R, Wasserman SM, Sabatine MS.
-
Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT.
-
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.
-
Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine MS; PROFICIO Investigators.
-
Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R.
About
-
Elevated levels of blood lipids are well-documented risk factors for cardiovascular disease. Hyperlipidaemia can be due solely to hereditary factors, but more commonly it is an acquired condition.
Load moreElevated levels of blood lipids are well-documented risk factors for cardiovascular disease. Hyperlipidaemia can be due solely to hereditary factors, but more commonly it is an acquired condition.
Statins are the preferred class of drugs to lower elevated low density lipoprotein cholesterol (LDL-C). There are other classes to augment or substitute for statins, such as esetimibe, fibrates, niacin and dietary supplements.
Load Less
Editor's choice
-
Renata CífkováEuropean Cardiology Review 2014;9(1):16–20
Videos
-
14 September 2018 -
03 September 2018 -
31 August 2018 -
24 April 2018 -
-
Pages
-
Junji KobayashiEuropean Cardiology Review 2018;13(2):132.DOI: https://doi.org/10.15420/ecr.2018.13.2.PO13
-
Doreen Tan Su-YinEuropean Cardiology Review 2018;13(2):112–4.DOI: https://doi.org/10.15420/ecr.2018.13.2.EO2
-
Rodrigo Alonso, Leopoldo Perez de Isla, Ovidio Muñiz-Grijalvo, et alEuropean Cardiology Review 2018;13(1):14–20.DOI: https://doi.org/10.15420/ecr.2018:10:2
-
Stephen J NichollsEuropean Cardiology Review 2018;13(1):9–13.DOI: https://doi.org/10.15420/ecr.2018.3.2
